


PRODUCT INFORMATION



SGI-7079

Item No. 20111

CAS Registry No.: 1239875-86-5
Formal Name: 3-[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-benzeneacetonitrile
MF: C₂₆H₂₆FN₇
FW: 455.5
Purity: ≥98%
UV/Vis.: λ_{max}: 285 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SGI-7079 is supplied as a crystalline solid. A stock solution may be made by dissolving the SGI-7079 in the solvent of choice, which should be purged with an inert gas. SGI-7079 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of SGI-7079 in these solvents is approximately 30 mg/ml.

SGI-7079 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SGI-7079 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SGI-7079 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SGI-7079 is an inhibitor of the receptor tyrosine kinase Axl.¹ It inhibits proliferation of inflammatory breast cancer cells (IC₅₀s = 0.43 and 0.15 μM for SUM149 and KPL-4 cells, respectively), decreases invasion, and halts the cell cycle in the G₁ phase. SGI-7079 synergistically increases the potency of erlotinib (Item No. 10483) on EGFR inhibition.² In a mouse xenograft model of non-small cell lung cancer, SGI-7079 dose-dependently inhibits tumor growth, an effect that is greater when used in combination with erlotinib.

References

1. Wang, X., Saso, H., Iwamoto, T., *et al.* TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. *Cancer Res.* **73**(21), 6516-6525 (2013).
2. Byers, L.A., Diao, L., Wang, J., *et al.* An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clin. Cancer Res.* **19**(1), 279-290 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM